Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

RCT (n=492) found that the addition of pegvorhyaluronidase alfa to nab-paclitaxel/gemcitabine improved the objective response rate (RR 1.29, 95% CI 1.03-1.63), but not the progression free, or overall survival. Results do not support the development of pegvorhyaluronidase alfa.

Journal of Clinical Oncology